Clinical Trial Update: Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 trial comparing maintenance eribulin mesylate to observation in triple negative breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• ERIBULIN MESYLATE (Eribulin mesylate)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: UNKNOWN